Logo

Regeneron Announces FDA Review Acceptance of EYLEA's sBLA for the treatment of Diabetic Retinopathy

Share this

Regeneron Announces FDA Review Acceptance of EYLEA's sBLA for the treatment of Diabetic Retinopathy

Shots:

  • The sBLA involves results of P-III PANORAMA trial assessing EYLEA treatment from moderate severe-to-severe non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME)
  • The announced PDUFA date for EYLEA by US FDA is 13 May- 2019. PANORAMA six months’ results has been announced in March 2018 with expected one year results in H2’18
  • EYLEA IV is currently approved in the US and indicated for the treatment of wet age-related macular degeneration- macular edema following retinal vein occlusion- DME- and DR in patients with DME

/ article | Ref: Regeneron | Image: Market exclusive


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions